Table 1.
Systemic inflammatory markers in obese pre-diabetic LH-21-treated mice.
| Systemic Inflammatory Markers | CONTROL | 45% HFD VEH | 45% HFD LH-21 | |||
|---|---|---|---|---|---|---|
| Leptin (pg/ml) | 4121 ± 749 | 19550 ± 8501** | 13720 ± 7917* | |||
| HMWAdiponectin (ng/ml) | 5397 ± 2679 | 2864 ± 746* | 2942 ± 1100* | |||
| IL-6 (pg/ml) | 51,7 ± 13,0 | 211,4 ± 107,6* | 183,4 ± 165,9* | |||
| CXCL1 (pg/ml) | 137,8 ± 29,9 | 383,9 ± 209,8* | 232,4 ± 169,5 | |||
| IL-5 (pg/ml) | 5,46 ± 1,78 | 8,99 ± 4,26 | 12,95 ± 11,67 | |||
| IL-2 (pg/ml) | 5,31 ± 1,59 | 5,20 ± 1,03 | 5,56 ± 1,46 | |||
| IL-12 p70 (pg/ml) | 61,41 ± 10,53 | 78,09 ± 19,51 | 95,73 ± 31,61 | |||
| IL-10 (pg/ml) | 23,23 ± 16,48 | 22,45 ± 11,86 | 26,11 ± 11,12 | |||
| IFN-γ (pg/ml) | 1,31 ± 0,71 | 1,45 ± 0,44 | 1,77 ± 0,68 | |||
The levels of leptin and HMW adiponectin in plasma were measured with a commercial ELISA. A mouse pro-inflammatory panel kit was used for the quantitative determination of IFN-γ, IL-2, IL-5, IL-6, CXCL1, IL-10 and IL-12p70 by multi-array electrochemiluminescence detection technology. n = 8–10 mice each group. One-way ANOVA and Bonferroni’s post-test, *p < 0.05, **p < 0.01 versus control.